Low Dose Atorvastatin Did Not Reduce Composite Endpoint in Patients with COVID-19
INSPIRATION-S led by Behnood Bikdeli, MD, MS, and presented at the American College of Cardiology 2021 Meeting, failed to show the efficacy of atorvastatin in reducing thrombotic events and all-cause…
ACTION-Coalition Trial: Therapeutic Dose of Anticoagulation Is Associated With Increased Risk of Bleeding and No Improvement in Clinical Outcomes Among Hospitalized COVID-19 Patients With Elevated D-Dimer Levels
ACTION presented at the American College of Cardiology 2021 meeting by Renato D. Lopes, MD, PhD, demonstrated that among patients hospitalized with COVID-19 and elevated D-dimer levels, therapeutic anticoagulation with full-dose…
Paclitaxel-Coated Devices Not Associated with Higher Mortality, Results from SAFE-PAD Show
Paclitaxel-coated balloons had come under fire in recent years, after a meta-analysis of randomized control trials involving their use for the treatment of peripheral artery disease found an associated with…
No benefit to FFR-guided PCI over angiographic-guided PCI of Nonculprit Lesions after STEMI: Results from FLOWER-MI Show
Key Points: While FFR-guided PCI is superior in chronic coronary syndrome, its role in primary PCI of acute coronary syndrome remained unknown. Patients with STEMI and multivessel disease, were randomized…
Aspirin Vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: The Host Exam Randomized Controlled Trial
KEY POINTS: Clopidogrel is superior to aspirin as chronic maintenance therapy after drug eluting stent (DES) placement with contemporary percutaneous coronary intervention (PCI) following 12 ± 6 months of dual…
Additional background and insight
Presented by Dr. Schuyler Jones, assistant professor of medicine, Duke University, and a member of the Duke Clinical Research Institute in the first Late Breaking Clinical Trial session, “Aspirin Dosing:…
REHAB-HF: A Novel Physical Rehabilitation Intervention For Older Patients With ADHF
Key Points: Elderly frail patients with acute decompensated heart failure hospitalizations benefit from cardiac rehabilitation Tailored rehabilitation led to a large, significant improvement in Short Physical Performance Battery (SPPB) score…
DAPT with Clopidogrel Superior to Ticagrelor one month after PCI: Results from the TALOS-AMI Trial
With the widespread use of second-generation drug eluting stents, it has become more apparent that the risk of stent thrombosis decreases significantly after the first thirty days. The risk of…
Ultrasound Guided Renal Denervation shown to Decrease Ambulatory Blood Pressure in Patients with Resistant Hypertension: Results from the RADIANCE-HTN TRIO Trial
While renal denervation has been shown to improve blood pressure in patients with moderate hypertension, its effects on resistant hypertension have been more modest. During Sunday’s Late Breaking Clinical Trials…
Relationship Between Omega-3 Fatty Acid Levels And Major Adverse Cardiovascular Outcomes In Patients With High Cardiovascular Risk
KEY POINT: There is not enough evidence to state whether Omega-3 Fatty Acid levels are beneficial or harmful against major adverse cardiovascular events in patients with high cardiovascular risk. Dr.…
Are ACE Inhibitors or Beta-Blockers Cardioprotective During Adjuvant Treatment for Early-Stage Breast Cancer?
New results were presented from the Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) trial at ACC 2021 on May 16 and published concurrently in Circulation . The…
PRADA: Cardioprotective Agents May Not Be Required During Breast Cancer Tx
Adjuvant breast cancer therapy, while beneficial in prolonging survival, has been shown to have harmful effects on the heart, prompting some providers to prescribe neurohormonal blocking agents to attenuate the…
TWILIGHT: Analysis Shows Sex Disparities in PCI Outcomes Still Exist
Women fared worse than men in terms of increased bleeding risk, but comparable to men for ischemic event rates, results of a subgroup analysis of the TWILIGHT study presented May…
Rivaroxaban shown to lower future vascular events after peripheral revascularization: results from VOYAGER-PAD
Rivaroxaban should be considered as adjunctive therapy to aspirin alone in patients undergoing peripheral limb revascularization, authors of the VOYAGER-PAD trial concluded today. In the Late Breaking Clinical Trials session…
Dapagliflozin in the Treatment of COVID-19: Insights from the DARE-19 Trial
SGLT-2 inhibitors have demonstrated efficacy in various cardiometabolic conditions, including heart failure, coronary artery disease, chronic kidney disease, and diabetes. Given its favorable profile in various disease states, and the…
Tricuspid Valve Replacement with the Transcatheter Evoque Valve is Safe and Effective at 30 days
Transcatheter tricuspid valve replacement has become a feasible alternative to surgery in patients deemed to be at high risk of adverse events, and in the past decade, various devices have…
Real-World Data Supports Continued use of Transcatheter Left Atrial Appendage Occlusion
The WATCHMAN left atrial appendage occluder device has been widely accepted as an alternative to oral anticoagulation for stroke prevention in patients with underlying atrial fibrillation. However, the indications for…
Apixaban Associated with Fewer Subclinical Valve Thrombosis Events: Results from the ATLANTIS 4D-CT Substudy
Subclinical valve thrombosis after transcatheter aortic valve intervention (TAVI) has emerged as a challenge to the standardization of antithrombotic therapy after valve implantation. Results of the randomized ATLANTIS trial, presented…
Apixaban not Superior to Standard of Care after TAVR in ATLANTIS
The administration of apixaban monotherapy after transcatheter aortic valve replacement is not superior to the standard of the care antithrombotic treatment, results of the randomized, phase IIIb, prospective, open label,…
Prospective ARNI Versus Ace Inhibitor Trial to Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction (PARADISE-MI)
KEY POINTS Sacubitril/valsartan did not provide a lower rate of cardiovascular death, heart failure hospitalization, or outpatient development of heart failure when compared to active treatment with ramipril in patients…